November 5, 2025
As earnings come with sentiment and expectation restraints, revenue declines, consensus and EPS misses following some with drug failures and regulatory concerns
Traders are looking to the ADP private payrolls report for clues about the labor market, alongside updates on mortgage applications and ISM services activity
News: Mesoblast (MESO) the FDA has scheduled a meeting in early December to discuss its data on opioid reduction and cessation from its 1st P3 study (MSB-DR003) of rexlemestrocel-L in patients with chronic low back pain (CLBP). The “FDA has emphasized the importance of developing non opioid treatments for chronic pain, and we look forward to discussing plans for rexlemestrocel-L as an agent that may result in both amelioration of CLBP as well as opioid reduction or cessation.”
Pre-open Signals: 3 Negative and 5 Positive Indications
Never leave an investor uninformed … I say what others won’t, so you can do what others can’t!
October 26, 2025
A sector catalyst
Novartis NVS) has agreed to buy Avidity Biosciences (RNA) closed up Friday +$0.60 or +1.24% to $49.15 for about $12 billion.
NVS will pay Avidity shareholders $72 a share in cash, a premium of 46% to the company’s Friday closing price.
Avidity Biosciences is a biopharmaceutical company. RNA is engaged in delivering a new class of ribonucleic acid (RNA) therapeutics called antibody oligonucleotide conjugates (AOCs). These AOCs are designed to combine the specificity of monoclonal antibodies with the precision of oligonucleotide therapies to address targets and diseases previously unreachable with existing RNA therapies.
November 4, 2025
November continued with C> sector’s collateral damage; so much for an initial seasonality non-boost as valuations and breath in decline
Pre-open Indication Scoring: 7 Hits and 2 Miss
35th day’s shutdown, 2nd month with 14th Democratic negative votes and counting
News: Royalty Pharma plc (RPRX) has acquired a royalty interest in Alnylam Pharmaceuticals’ (ALNY -$10.45 or -2.41% to $423.47) AMVUTTRA from funds managed by Blackstone Life Sciences (BLS) for $310 M. The royalty interest being sold stems from BLS’ financing with ALNY, to support AMVUTTRA’s pivotal P3 HELIOS-B trial.
RMi collects, interprets and disseminates cell and gene therapy sector (C>) fact-based news, trusted and verified intel and share pricing data to bridge the gap to an investment decision
Never leave an investor uninformed!
October 26, 2025
A sector catalyst Novartis NVS) has agreed to buy Avidity Biosciences (RNA) closed up Friday +$0.60 or +1.24% to $49.15 for about $12 billion. NVS will pay Avidity shareholders $72 a share in cash, a premium of 46% to the company’s Friday closing price. Avidity Biosciences is a biopharmaceutical company. RNA is engaged in delivering a new class of ribonucleic acid (RNA) therapeutics called antibody oligonucleotide conjugates (AOCs). These AOCs are designed to combine the specificity of monoclonal antibodies with the precision of oligonucleotide therapies to address targets and diseases previously unreachable with existing RNA therapies.
October 24, 2025
ADVM is up +$0.14 or +3.349% to $4.32 ADVM's lead program, Ixo-vec, is a P3 intravitreal gene therapy designed to treat vision loss associated with wet age-related macular degeneration with a single intravitreal dose Ixo-vec is designed as a single 1-time treatment to deliver continuous and stable intraocular aflibercept levels, thereby reducing the significant patient burden associated with current chronic anti-VEGF therapies, while also potentially leading to improved vision outcomes.
October 15, 2025
Who is pumping the volume thus the price, after the usual small and inching volume or no volume Challenging and questionable "aspects" state the obvious – a Ponzi Scheme! They’re BROKE filing with yet another PPM unfulfilled! What valuation model would even/ever justify a PPM pricing? Accumulated deficit to date= $103.2 M in 12 years WHO is their major shareholder – DST Capital and itsDAILY buyer, OTCQB: HRGN’s in-house fund run by its president Hong Yu, funded by Mrs. bin (Zhao) of Weston, Mass. ??? U.S. investors BEWARE, forewarned is forearmed?
1 hour 23 min ago
RMi pre-open: Skepticism
© 2025 RegMed Investors (regmedinvestors.com), all rights are reserved.
RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.
The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.
The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.
